Literature DB >> 2124961

Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.

B Brooks1, K Chapman, J Lawry, A Meager, R C Rees.   

Abstract

Recombinant human interleukin-4 (rhIL-4) and transforming growth factor-beta 1 (TGF-beta 1) suppressed the induction of lymphokine-activated killer (LAK) activity induced by recombinant human interleukin-2 (rhIL-2) in peripheral blood lymphocytes. DNA synthesis and the expression of the p55 alpha chain of the IL-2 receptor (Tac antigen) were also inhibited. The inhibitory effect was greatest when these factors were added during the first 48 h of a 4-day culture, with reduced cytolytic activity against both natural killer (NK) resistant and NK-sensitive tumour cell line targets. The suppressive action of both cytokines was accompanied by a reduction in tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) levels in lymphocyte culture supernatants. Recombinant human IFN-gamma (rhIFN-gamma), but not recombinant human TNF-alpha (rhTNF-alpha) was able to overcome the inhibitory effect of recombinant human interleukin-4 (rhIL-4) on LAK induction and DNA synthesis but not Tac antigen expression. However, cytotoxicity induced by rhIFN-gamma alone was also suppressed by rhIL-4 and TGF-beta 1, inferring that rhIFN-gamma-mediated abrogation of rhIL4 suppression was not simply a direct IL-2-independent effect on cytotoxicity. In addition, rhIL-4 did not increase TGF-beta production from rhIL-2-activated peripheral blood mononuclear cells, suggesting that rhIL-4 did not mediate reduction of rhIL-2 responses through the induction of TGF-beta release.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2124961      PMCID: PMC1535485          DOI: 10.1111/j.1365-2249.1990.tb05494.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  50 in total

1.  Cytokine gene expression during the generation of human lymphokine-activated killer cells: early induction of interleukin 1 beta by interleukin 2.

Authors:  E J Kovacs; S K Beckner; D L Longo; L Varesio; H A Young
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

2.  Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.

Authors:  W L Crump; L B Owen-Schaub; E A Grimm
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

3.  Evidence for IL-2 independent proliferation in human T cells.

Authors:  T J Laing; A Weiss
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

Review 4.  Transforming growth factor beta.

Authors:  A B Roberts; M B Sporn
Journal:  Adv Cancer Res       Date:  1988       Impact factor: 6.242

5.  Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells.

Authors:  G Gallagher; F Wilcox; F al-Azzawi
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

6.  Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.

Authors:  B Brooks; R C Rees
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

7.  Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.

Authors:  S Sone; T Utsugi; A Nii; T Ogura
Journal:  J Natl Cancer Inst       Date:  1988-05-18       Impact factor: 13.506

8.  Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.

Authors:  A Kasid; G I Bell; E P Director
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

9.  Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation.

Authors:  S M Wahl; D A Hunt; H L Wong; S Dougherty; N McCartney-Francis; L M Wahl; L Ellingsworth; J A Schmidt; G Hall; A B Roberts
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

10.  Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors.

Authors:  L B Owen-Schaub; W G Loudon; M Yagita; E A Grimm
Journal:  Cell Immunol       Date:  1988-01       Impact factor: 4.868

View more
  9 in total

1.  HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.

Authors:  Maria A De Francesco; Manuela Baronio; Simona Fiorentini; Costantino Signorini; Carlo Bonfanti; Claudio Poiesi; Mikulas Popovic; Manuela Grassi; Emirena Garrafa; Luisa Bozzo; George K Lewis; Stefano Licenziati; Robert C Gallo; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

2.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  CD4+ T-helper-cell responses in mice with low-level Candida albicans infection.

Authors:  A Mencacci; R Spaccapelo; G Del Sero; K H Enssle; A Cassone; F Bistoni; L Romani
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

4.  Interleukin-2-activated human effector lymphocytes mediate cytotoxicity by inducing apoptosis in human leukaemia and solid tumour target cells.

Authors:  C R Knight; R C Rees; A Platts; T Johnson; M Griffin
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

5.  Interferon-alpha inhibits murine macrophage transforming growth factor-beta mRNA expression.

Authors:  S Dhanani; M Huang; J Wang; S M Dubinett
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

6.  Differential cytokine regulation of natural killer cell-mediated necrotic and apoptotic cytotoxicity.

Authors:  C M Gardiner; D J Reen
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

Review 7.  Transforming growth factor-beta and its implication in the malignancy of gliomas.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Target Oncol       Date:  2014-03-05       Impact factor: 4.493

8.  The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2.

Authors:  C R Carter; B W Hancock; R C Rees
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Killer-cell inhibitory receptors, CD158a/b, are upregulated by interleukin-2, but not interferon-gamma or interleukin-4.

Authors:  T Kogure; H Fujinaga; A Niizawa; L X Hai; Y Shimada; H Ochiai; K Terasawa
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.